Open AccessInfection risk with the use of interleukin inhibitors in hospitalized patients with COVID-19: A narrative review
Author(s) -
Thoyaja Koritala,
Vishwanath Pattan,
Raghavendra Tirupathi,
Ali A. Rabaan,
Abbas Al Mutair,
Saad Alhumaid,
Ramesh Adhikari,
Keerti Deepika,
Nitesh Jain,
Vikas Bansal,
Aysun Tekin,
Simon Zec,
Amos Lal,
Syed Anjum Khan,
Juan Pablo Domecq Garces,
Omar M Abu Saleh,
Salim Surani,
Rahul Kashyap
Publication year - 2021
Publication title -
le infezioni in medicina
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.395
H-Index - 22
eISSN - 2532-8689
pISSN - 1124-9390
DOI - 10.53854/liim-2904-1
Subject(s) - medicine , placebo , canakinumab , incidence (geometry) , tocilizumab , anakinra , odds ratio , meta analysis , medline , relative risk , randomized controlled trial , confidence interval , pathology , alternative medicine , physics , disease , political science , law , optics
To date, only corticosteroids and interleukin-6 (IL-6) inhibitors have been shown to reduce mortality of hospitalized patients with COVID-19. In this literature review, we aimed to summarize infection risk of IL inhibitors, with or without the use of corticosteroids, used to treat hospitalized patients with COVID-19.